Division of Gastroenterology, Hepatology and Nutrition, Loyola University Medical Center, Maywood, IL 60153, USA.
Angiology. 2012 Apr;63(3):206-12. doi: 10.1177/0003319711411705. Epub 2011 Jul 6.
The treatment of hepatocellular cancer (HCC) with transarterial chemoembolization (TACE) prior to orthotopic liver transplant (OLT) is of increasing importance due to the rise in HCC incidence and donor shortage. This single-center study examines 28 patients treated with TACE and 7 patients not treated with TACE, with HCC prior to OLT between 1999 and 2008. The overall 1- and 5-year survival of all transplanted patients with HCC was 94% (33 of 35) and 80% (28 of 35). There was no difference in survival (P = .99) between patients who underwent transplantation immediately (median 95 days) and patients who had significantly longer wait times (median 308 days) when treated with TACE. During extensive wait times for OLT, TACE can be used to keep patients with HCC on the waiting list by preventing tumor progression, with similar outcomes compared with those who underwent transplantation immediately.
经动脉化疗栓塞（TACE）在原位肝移植（OLT）前治疗肝细胞癌（HCC）的重要性日益增加，因为 HCC 的发病率上升和供体短缺。这项单中心研究检查了 1999 年至 2008 年间，28 例接受 TACE 治疗和 7 例未接受 TACE 治疗的 HCC 患者。所有接受 HCC OLT 的移植患者的总体 1 年和 5 年生存率分别为 94%（33/35）和 80%（28/35）。未接受 TACE 治疗的患者，其立即进行移植（中位时间 95 天）和 TACE 治疗后等待时间明显延长（中位时间 308 天）的患者之间的生存差异无统计学意义（P =.99）。在 OLT 的广泛等待时间内，TACE 可通过防止肿瘤进展，使 HCC 患者继续留在等待名单上，与立即进行移植的患者相比，具有相似的结果。
